Skip to content

Gross Profit at other companies

Baxter International logo
Baxter InternationalBAX
$891M+3.5%
PTH
Pelthos Therapeutics Inc.PTHS
$9.23M
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$54.21M+10.8%
RFL
Rafael Holdings, Inc.RFL
$131K-56.3%
Opko Health logo
Opko HealthOPK
$45.76M+7.4%
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$9.1M-22.0%
Operating income-$3.1M-342%
Net income-$3.3M-362%
EPS (diluted)-$0.22-375%

Balance sheet

See full
Cash & equivalents$11.0M-27.1%
Total debt$4.8M-7.1%
Total equity$21.6M-24.5%
Total assets$71.0M+1.5%

Cash flow

See full
Operating cash flow$387.0K-90.1%
CapEx--100%
Free cash flow$387.0K-89.9%

Valuation

See full
Market cap$97.09M+142%
Enterprise value$90.91M+212%
P/S2.3×+1.4×

Profitability

See full
Gross margin82.9%-1.4pp
Operating margin-17.2%-125pp
Net margin-17.6%-103pp
FCF margin3.3%

Returns & leverage

See full
Return on equity-29.4%-86.3pp
Debt / equity0.2×0.0×
Current ratio-0.3×

Where this comes from

Calculated from Cumberland Pharmaceuticals’s reported figures.

The official record: Cumberland Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cumberland Pharmaceuticals's gross profit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cumberland Pharmaceuticals's gross profit?
Cumberland Pharmaceuticals (CPIX) reported gross profit of $7.2M in Q1 2026.
How has Cumberland Pharmaceuticals's gross profit changed year-over-year?
Cumberland Pharmaceuticals's gross profit decreased by 30.0% year-over-year, from $10.29M to $7.2M.
What is the long-term trend for Cumberland Pharmaceuticals's gross profit?
Over 4 years (2021 to 2025), Cumberland Pharmaceuticals's gross profit has grown at a 8.6% compound annual growth rate (CAGR), from $27.17M to $37.85M.
What does gross profit mean?
Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.